perzinfotel

Perzinfotel is a small molecule drug that acts as a potent and selective competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor. It exhibits approximately tenfold selectivity for the NR1-NR2A subunit combination over other NMDA receptor subtypes. Perzinfotel has demonstrated neuroprotective effects in preclinical studies and was investigated primarily for the treatment of stroke and neuropathic pain. Despite its promising safety profile compared to older NMDA antagonists and its lack of significant analgesic effects or adverse cardiorespiratory events, development was discontinued after phase II trials due to limited efficacy or strategic reasons. The drug’s oral bioavailability is low (3–5%), leading to exploration of prodrugs for improved delivery[1][5][6][7].

Other names

perzinfotelEAA-090EAA090EAA 090WAY-126090WAY126090WAY 126090